Skip to content
Review

From acute intervention to chronic management: Biopharmaceutical barriers and advanced formulation strategies for Peroral metronomic chemotherapy.

Nov 2026 · Advanced Drug Delivery Reviews · pp. 115988 · 0 citations · 200 references
Medicine

Abstract

Although cancer is a chronic disease, conventional oncology has largely relied on maximum tolerated dose (MTD) chemotherapy to achieve rapid tumor killing. However, the limited specificity of these agents frequently results in substantial systemic toxicity and necessitates prolonged treatment-free intervals that may permit tumor regrowth and therapeutic resistance. Metronomic chemotherapy (MET) has emerged as a promising alternative approach, characterized by continuous or intermittent administration of low-dose chemotherapeutic agents over extended periods (often incorporating scheduled drug-free breaks ranging from daily up to weekly). Rather than relying primarily on direct cytotoxicity, MET exerts anti-tumor effects through repeated anti-angiogenic activity, immune modulation, and alteration of tumor microenvironment, while minimizing treatment-related toxicity. These properties make MET particularly attractive for long-term cancer management. Despite its clinical promise, broader implementation of MET remains constrained by challenges associated with drug delivery and administration. For chronic therapeutic regimens, the peroral route represents the most practical and patient-friendly option, offering improved adherence, reduced healthcare burden, and fewer hospital visits. However, many chemotherapeutic agents possess poor aqueous solubility, limited membrane permeability, and unfavorable pharmacokinetic properties, resulting in inadequate peroral bioavailability. In this review, we discuss the evolving role of MET in cancer treatment, compare available routes of administration, and examine the major biopharmaceutical barriers to effective peroral delivery. We further highlight emerging formulation strategies and advanced drug delivery systems designed to overcome these limitations. Collectively, these advances may facilitate the transition of cancer therapy from an episodic, high-intensity intervention toward a sustainable long-term disease management strategy.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.